Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
8(47%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
10
59%
Ph phase_3
1
6%
Ph phase_1
6
35%

Phase Distribution

6

Early Stage

10

Mid Stage

1

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
6(35.3%)
Phase 2Efficacy & side effects
10(58.8%)
Phase 3Large-scale testing
1(5.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

8

trials recruiting

Total Trials

17

all time

Status Distribution
Active(9)
Completed(3)
Other(5)

Detailed Status

Recruiting6
unknown5
Completed3
Active, not recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
8
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (35.3%)
Phase 210 (58.8%)
Phase 31 (5.9%)

Trials by Status

active_not_recruiting212%
recruiting635%
unknown529%
completed318%
not_yet_recruiting16%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT07466927Phase 2

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

Not Yet Recruiting
NCT05076682Phase 2

Reverse Triple Negative Immune Resistant Breast Cancer

Recruiting
NCT05582499Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting
NCT04400188Phase 1

A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer

Completed
NCT06754930Phase 1

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

Recruiting
NCT06778031Phase 2

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

Recruiting
NCT06237257Phase 2

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

Active Not Recruiting
NCT04303988Phase 2

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

Recruiting
NCT04562337Phase 2

SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC

Active Not Recruiting
NCT05205200Phase 2

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Recruiting
NCT03995472Phase 1

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Completed
NCT03133247Phase 1

A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients

Completed
NCT03711305Phase 3

Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Unknown
NCT04979390Phase 1

Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors

Unknown
NCT04647357Phase 2

A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer

Unknown
NCT03732508Phase 2

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Unknown
NCT03474289Phase 1

Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors

Unknown

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17